← Search & browse all drugs
NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Carboxamide derivatives
rufinamide
N03AF03
Forms & Strengths
- Tablets: 200 mg, 400 mg
- Oral Suspension: 40 mg/mL
Adult Dosing
- Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in adults and pediatric patients aged 1 year and older.
- Initial dose: 400 mg/twice daily, increased by 400 mg/day every 2 days up to a maximum recommended dose of 3200 mg/day administered in two divided doses.
Pediatric Dosing
- Pediatric patients 1 year and older (Lennox-Gastaut syndrome):
- Initial dose: 10 mg/kg/day in two divided doses, titrated upward by approximately 10 mg/kg increments every 2 days to a maximum of 45 mg/kg/day (not to exceed 3200 mg/day) in two divided doses.
Indications
- Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 year of age and older.
Mechanism of Action
- Triazole derivative anticonvulsant that modulates the activity of sodium channels, specifically prolonging the inactive state of the voltage-gated sodium channel.
Contraindications
- Known hypersensitivity to rufinamide or families of triazole derivatives.
- Familial Short QT syndrome.
Adverse Reactions
- Somnolence
- Vomiting
- Pyrexia
- Fatigue
- Dizziness
- Nausea
- Gait disturbance
- Shortening of the QT interval
Drug Interactions
- Hormonal contraceptives: Rufinamide may decrease the efficacy of estrogen- and progestogen-containing contraceptives.
- Valproate: Increases rufinamide plasma concentrations, requiring lower target doses of rufinamide.
- CYP3A4 inducers (e.g., carbamazepine, phenobarbital, primidone): May decrease rufinamide plasma concentrations.
Curated Content: Needs Vetting Before Put to Clinical Use